Perform Security Risk Assessment and Budget Projections
- Analyze the risk profile of the following described corporation, using the Ryan-Nichols risk equation and other tools that help you decide /recommend best course of action to CEO who has hired your team to do:
Corporation description:
Pfizer Medical firm, with $51.75 Billion in revenues per year and 120,000 employees located in 72 countries worldwide with 13 specialized Research facilities in 5 secret locations. Research is conducted using laboratory testing, computer simulation and modeling, and requires worldwide sharing of data from test results. The company must get its products approved by every country that it sells them in, and the faster it gets them to market, the longer it can benefit from the exclusivity granted by patent protection. In fact, the company recently shepherded a new schizophrenia drug through the approval process in 17 countries using its intranet: it brought the drug to market in only 18 months and generated over $550 million revenue in the first 14 months on the market.
Pfizer is currently engaged in medical research to combat Covid-19 worldwide.
According to Albert Bourla, CEO & Chairman of Pfizer:
Many small firms are among those screening drug libraries or existing therapies for activity against SARS-CoV-19, the virus that causes COVID-19. Unlike a Big Pharma the size of Pfizer, these young biotech’s may not be familiar with the path they'll need to take as they get to later stages of drug development, or how to deal with the regulatory process.
“Pfizer is committed to sharing our clinical development and regulatory expertise to support the most promising candidates these companies bring forward,” the company said.
A critical element of the drug R&D know-how lies in human capital. Pfizer has created “a SWAT team” with experts from different disciplines and segments dedicated to addressing the current pandemic.
To get any potential drugs or vaccines to the world as soon as possible after approval, Pfizer will also help produce them at its facilities. “Pfizer is committed to using any excess manufacturing capacity and to potentially shifting production” when needed, the company said.
Pfizer’s long been ranking among the top three pharma companies by worldwide sales, with 2019 revenues of $51.75 billion. It’s also the seller of the world’s best-selling vaccine, Prevnar 13, for the prevention of infection by pneumococcal bacteria.
The company’s now developing its own potential antiviral therapies and is also in advanced talks with Germany’s BioNTech over ex-China development of an mRNA coronavirus vaccine. The prophylactic candidate, dubbed BNT162, has just been licensed to China’s Fosun Pharma in that country. A global clinical study in Europe, the U.S. and China is being planned.
Pfizer’s efforts will also not stop with this outbreak. After seeing repeated failures from the global community to contain deadly pathogens in their infancy, Pfizer is now looking into building a framework for similar health threats in the future. It’s reaching out to U.S. government agencies, including the NIH, to “build a cross-industry rapid response team of scient